Full Press Release Details
CEO Issues Letter to Shareholders
Ness Ziona, Israel - December 5, 2017 -
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV)
today released a Letter from the CEO regarding recent activities and plans.
2017 Highlights and 2018 Plans:
January 2017: Marius Nacht's aMoon Partners fund
invests in BiondVax, becoming our largest shareholder. Nacht is co-founder and Chairman of Check Point Software Technologies Ltd.
(Nasdaq: CHKP). aMoon is a new Israeli healthcare fund.
March: Israel Ministry of Economy grant towards construction
of mid-size commercial manufacturing facility in Jerusalem. Planned production of batch for Phase 3 trial's second participant
group. In July, we secured a lease for an entire floor (approximately 20,000 square feet or 1800m2) in the Jerusalem
June: The European Investment Bank (EIB) entered into
a 20m (approximately $23m) non-dilutive funding agreement to support the Phase 3 trial and complete the set up of our manufacturing
July: Statistically significant results from our European
Union UNISEC consortium Phase2b clinical trial: M-001 is deemed safe and induces significant cellular immunity. Our UNISEC colleagues
are in the process of submitting an article for publication in a peer-reviewed science journal.
September: Raised $10m in secondary offering. Following
the placement, BiondVax has 3 large strategic investors holding a total of over 30%, with Marius Nacht's aMoon Partners fund
remaining our largest current shareholder.
October: Began regulatory procedures with the European
EMA (akin to the American FDA) regarding Phase 3 trial plans.
November: Signed clinical trial agreement (CTA) for a
Phase 2 trial conducted by the U.S. NIH. The NIH-funded trial will include 120 participants with sites in Texas, Ohio, Missouri,
and Iowa. This, our first trial in the US under an FDA IND, is planned for Q2 2018, and is in addition to our planned Phase 3 trial
January 2018: Trading will be consolidated on Nasdaq
following our voluntary delisting from the Tel Aviv Stock Exchange effective January 22. Final day of trading on TASE will be January
18. Shareholder FAQ in Hebrew at http://bit.ly/BVXV-TASE.
Keep in touch: Join our mailing list from www.biondvax.com
or email j.phillipson@biondvax.com
About BiondVax Pharmaceuticals Ltd
BiondVax is a clinical phase biopharmaceutical
company developing a universal flu vaccine. The vaccine candidate is designed to provide multi-season protection against most
seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of
conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting
and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.
For further information, please contact:
+972-8-930-2529 x5105
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe,"
"intend," "plan," "continue," "may," "will," "anticipate,"
and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks
and uncertainties reflect the management's current views with respect to certain current and future events and are subject
to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves
a lengthy and expensive process with uncertain outcome, the results of the contemplated Phase 2 & 3 trials, delays
or obstacles in launching and/or successfully completing our clinical trials, the impact of the global economic environment
on the Company customer target base, the adequacy of available cash resource and the ability to raise capital when needed. More
detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors"
in our Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission,
or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with
the SEC and the Tel-Aviv Stock Exchange.